11 – 12 May 2017 | New York, NY

  • Lady Liberty



  • myCME
  • City Skyline
  • myCME
11 – 12 May 2017  |  The Roosevelt Hotel, New York City

15th Annual CME Symposium

This advanced CME activity will provide participants with state-of-the-art information and practical guidance from internationally recognized experts on progress in managing HIV, hepatitis B, and hepatitis C, including drug development and treatment, management of important comorbidities and drug-drug interactions, enabling practitioners to deliver the highest quality care in all practice settings.

The primary goals of this activity are to increase each participant’s competence to:

  • •  Illustrate advances in approaches to prevent and treat HIV infection, hepatitis B and hepatitis C
  • •  Apply new information to manage disease in difficult-to-treat situations
  • •  Manage patients with immune activation or immunosuppression
  • •  Understand, avoid and manage drug-drug interactions complicating treatment
  • •  Manage common and important comorbidities in patients with HIV infection, including cardiovascular,
       neoplastic, neurocognitive and sexually transmitted disorders and diabetes mellitus
  • •  Identify important management considerations in patients coinfected with multiple viral infections
  • •  Recognize that due to ongoing risk of liver disease, long-term care of patients with chronic viral hepatitis is
       often necessary, even after cure of the infection

Target Audience

The state-of-the art curriculum offered at this activity is designed to meet the needs of Infectious Disease Physicians, Hepatologists, Gastroenterologists, Internists, Family Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, and others involved in frontline HIV and Hepatitis patient care and treatment.

This CME activity is made possible, in part, by educational grants provided or pledged by:

 Gilead Sciences
 AbbVie, Bristol-Myers Squibb, Merck
 Janssen Therapeutics